Trial intelligence / Profile preview

Metformin for protection of ovarian reserve and function after chemotherapy in cervical cancer survivors

ChiCTR1900023488Phase 4Recruiting

Sponsor
Tongji Hospital
Start
Oct 2019
Modality
Small Molecules
Countries
1
01

Overview

Phase 4 trial of metformin in Cervical Cancer (CC) and ovarian injury (2 arms), sponsored by Tongji Hospital. Primary endpoint: Anti-Mullerian hormone. Started Oct 2019; status: recruiting.

02

Drugs

metformin
03

Conditions

Cervical Cancer (CC)ovarian injury

Beyond the preview

Go deeper on ChiCTR1900023488.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR1900023488.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call